Skip to Content

Data from the BRCAAway Study Confirms Better PFS & Efficacy with a Combination of Olaparib + Abiraterone Prednisone

In this MEDtalk, Dr. Maha Hussain presents data from the BRCAAway study. The study demonstrates that combining abiraterone & prednisone with olaparib improves efficacy and progression-free survival in metastatic castration-resistant prostate cancer patients with BRCA1/2 or ATM mutation.

Maha H. A. Hussain

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top